You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - other biologic treatment
SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tanaka Y, Takeuchi T, Umehara H, et al
SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort
Annals of the Rheumatic Diseases 2017;76:842.